Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are not sufficient to control the virtually inevitable emergence of motor response complications in advanced stages of the disease. Opportunity in this arena has spurred the development of a range of new therapies targeting motor symptoms in PD. With the recent launches of Rytary, Xadago, and Gocovri, and with half a dozen others in late-phase development, understanding how prescribers perceive and plan to incorporate new brands is crucial for developers facing a complicated, highly genericized, and increasingly competitive market.
DRG’s Special Topics reports use quantitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report on Parkinson’s disease will help developers gauge the competitiveness of their late-phase pipeline candidates and design messages to support or defend their market position.
Markets covered: United States
Primary research: Survey of 101 U.S. neurologists
Key companies: Impax Laboratories, Intec Pharma, NeuroDerm, Mitsubishi Tanabe Pharma, US WorldMeds, Newron Pharmaceuticals, Bial, Adamas Pharmaceuticals, Acorda Therapeutics, Sunovion Pharmaceuticals, Sumitomo Dainippon Pharma
Key drugs: Rytary, AP-CD/LD, ND-0612, apomorphine pump, Xadago, Ongentys, Gocovri, Inbrija, APL-130277, Apokyn
Key insights provided: